|
Apr 3
|
Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound?
|
|
Mar 5
|
ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y
|
|
Mar 5
|
Q4 2024 Esperion Therapeutics Inc Earnings Call
|
|
Mar 4
|
Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates
|
|
Mar 4
|
Esperion Therapeutics: Q4 Earnings Snapshot
|
|
Mar 4
|
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
|
|
Mar 3
|
Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia
|
|
Mar 1
|
Is Esperion Therapeutics, Inc. (ESPR) the Best Small Cap Pharma Stocks to Buy Now?
|
|
Jan 2
|
Esperion to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
|